Conference Coverage (Retrovirus)

65 Percent of Late-Stage AIDS Patients Respond to 3-Drug Combo

Published in AIDS Weekly, February 3rd, 1997

HIV dropped to undetectable levels in the majority of late-stage AIDS patients treated with three-drug combination therapy.

The patients, who had a median CD4 count of 15 cells/(mu)L when the study began, had a median CD4 increase of 86 cells/(mu)L after 24 weeks of the three-drug treatment.

The aggressive treatment used Merck's indinavir (IDV) protease inhibitor and two nucleoside analog reverse transcriptase inhibitors (NARTIs), zidovudine (AZT) and lamivudine (3TC). Glaxo Wellcome manufactures AZT and 3TC.

The findings were announced by Martin Hirsch of Massachusetts General Hospital at the Fourth Conference on Retroviruses...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-02-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry